Bausch + Lomb has abandoned its next great hope in glaucoma after the eye drops flunked a phase 2 study. The eye health company had been evaluating the alpha-2B agonist, dubbed BL1107, in a mid-stage study of 159 patients with primary open-angle glaucoma or ocular hypertension. The aim of the study was to show an improvement in visual sensitivity from baseline at Day 28. Despite a smaller phase 1/...